Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CMS Coverage-With-Evidence-Development Policy Could Face Revamp

This article was originally published in The Gray Sheet

Executive Summary

CMS is taking comments through Jan. 6 on implementation of CED policies as part of national coverage determinations, how CED impacts Medicare beneficiaries and how new approaches might maximize benefits.

You may also be interested in...



Local Coverage With Evidence Development Is Legit, CMS Says; But It May Be Rare

CMS issued its final guidance on the coverage-with-evidence-development program, two years following a draft. It is explicit that local Medicare contractors can employ CED in setting coverage policies in their jurisdictions, but it is not clear that the language will encourage significant use at the local level. The guidance also revises its approach on ending CED policies compared to what was stated in the 2012 draft guidance.

CMS Ambiguous On Role Of Local Contractors In Coverage With Evidence Development

Activities by Medicare contractors were among several matters that were addressed in CMS’ recent CED draft guidance that may not be fully clarified until the updated guidelines are put into practice, experts say.

Washington Roundup, May 2012

The latest medical device regulatory and reimbursement news from Elsevier Business Intelligence’s “The Gray Sheet.” This month we report on the new Medicare coverage policy for transcatheter aortic valve replacement and Medicare latest hospital inpatient payment proposal.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT030718

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel